Immitra Bio
Summary active Updated Jul 24, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Immitra Bio is a Swiss biotech developing a platform for scalable, one-time curative in-vivo gene editing therapies based on a mutation-agnostic gene editing technology paired with a digital target identification pipeline 123. Unlike conventional ex-vivo approaches, the platform is designed to avoid stem cell manipulation and patient conditioning 13. Its lead candidate, IB-003, is being developed as a potential one-time curative treatment for an inherited anemia 12. The company is headquartered in Plan-les-Ouates in the Geneva canton and is led by CEO Jan Nelis 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-21 | Pre-Seed | €2.58M | Backbone Ventures | OCCIDENT (co-lead), Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation 123 |
The round comprised CHF 2.25M (~€2.42M) from venture capital and private investors plus CHF 150k (~€161.8k) in non-dilutive funding 12. Proceeds will primarily support preclinical proof-of-concept studies for lead candidate IB-003 12.
What Investors Say
No independently sourced investor commentary found beyond the announcement press release.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
Immitra Bio press release, “Immitra Bio Secures CHF 2.4M / USD 3M in Pre-Seed Funding,” July 21, 2026. Accessed July 24, 2026. https://immitrabio.com/press/2026/20260721_pre-seed_announcement.html↩↩↩↩↩↩↩
-
Startupticker.ch, “CHF 2.4m pre-seed funding to advance ImmitraBio scalable in-vivo gene editing platform and lead asset,” July 2026. Accessed July 24, 2026. https://www.startupticker.ch/en/news/chf-2-4m-pre-seed-funding-to-advance-immitrabio-scalable-in-vivo-gene-editing-platform-and-lead-asset↩↩↩↩↩↩
-
EU-Startups, “Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform,” July 22, 2026. Accessed July 24, 2026. https://www.eu-startups.com/2026/07/zurich-based-immitra-bio-secures-e2-58-million-to-scale-its-scalable-in-vivo-genetic-medicine-platform/↩↩↩